A new study has found a link between high levels of air pollution at an individual’s
home address and an elevated risk of developing cardiovascular disease.
Air pollution exposure appears to heighten the production of inflammatory cells
in the bone marrow, triggering inflammation of the arteries.
These findings implicate air pollution exposure as an underrecognized risk factor for cardiovascular disease and suggest therapeutic targets beyond pollution mitigation to lessen the cardiovascular impact of air pollution exposure.
Shady Abohashem, MD Massachusetts General Hospital
BOSTON – Tiny particles of air pollution — called fine particulate matter — can have a range of effects on health, and exposure to high levels is a known risk factor for cardiovascular disease. New research led by investigators at Massachusetts General Hospital (MGH) reveals that fine particulate matter has a detrimental impact on cardiovascular health by activating the production of inflammatory cells in the bone marrow, ultimately leading to inflammation of the arteries. The findings are published in the European Heart Journal.
The retrospective study included 503 patients without cardiovascular disease or cancer who had undergone imaging tests at MGH for various medical reasons. The scientists estimated participants’ annual average fine particulate matter levels using data obtained from the U.S. Environment Protection Agency’s air quality monitors located closest to each participant’s residential address.
Over a median follow-up of 4.1 years, 40 individuals experienced major cardiovascular events, such as heart attacks and strokes, with the highest risk seen in participants with higher levels of fine particulate matter at their home address. Their risk was elevated even after accounting for cardiovascular risk factors, socioeconomic factors, and other key confounders. Imaging tests assessing the state of internal organs and tissues showed that these participants also had higher bone marrow activity, indicating a heightened production of inflammatory cells (a process called leukopoiesis), and elevated inflammation of the arteries. Additional analyses revealed that leukopoiesis in response to air pollution exposure is a trigger that causes arterial inflammation.
“The pathway linking air pollution exposure to cardiovascular events through higher bone marrow activity and arterial inflammation accounted for 29% of the relationship between air pollution and cardiovascular disease events,” says co–first author Shady Abohashem, MD, a cardiovascular imaging fellow at MGH. “These findings implicate air pollution exposure as an underrecognized risk factor for cardiovascular disease and suggest therapeutic targets beyond pollution mitigation to lessen the cardiovascular impact of air pollution exposure.”
Co–first author Michael Osborne, MD, a cardiologist at MGH, explains that therapies targeting increased inflammation following exposure to fine particulate matter may benefit patients who cannot avoid air pollution. “Importantly, most of the population studied had air pollution exposures well below the unhealthy thresholds established by the World Health Organization, suggesting that no level of air pollution can truly be considered safe,” he says. This work was supported by the National Institutes of Health.
About the Massachusetts General Hospital Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
Mass General Brigham has received a $50 million gift that will shape the future of cancer care and discovery by empowering the next generation of gene and cell therapy research.
The Sean M. Healey & AMG Center for ALS at Mass General Brigham has contracted with Keros Therapeutics, Inc. (Keros) to design a new Healey ALS MyMatch trial evaluating rinvatercept (KER-065).
The Sean M. Healey & AMG Center for ALS at Mass General Brigham is pleased to announce that the first participant received study medication in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 by Neurizon Therapeutics.
Investigators from Mass General Brigham analyzed data from nearly 4,300 stable outpatients with chest pain and no known prior CAD and found that, although women had smaller plaque volumes and fewer plaques with high-risk characteristics, they experienced similar rates of MACE compared with men.
In a Phase 3 randomized trial, Mass General Brigham researchers found that stereotactic radiation targeting individual tumors led to lower symptom burden, better cognitive outcomes, and better day-to-day function when compared with whole brain radiation.
Mass General Brigham study highlights the efficacy of proton therapy in reducing toxicity while enhancing outcomes for patients with lower grade gliomas compared to traditional radiotherapy.